Update on Immune Globulin Supply in Canada
Dear IG patient/caregiver,
As we have informed you since May, Canadian Blood Services experienced a shortage of the SCIg product Cuvitru.
Due to an increase in supply of Cuvitru in recent weeks, this shortage is no longer active and supplies are now at normal levels.
Patients currently receiving SCIG (Cuvitru)
Currently treated patients should continue with NO changes to their current access to SCIg. Patients that were switched to alternates will continue on alternates until further notice.
All vial sizes should be in good supply, and vial substitutions should cease.
Patients currently receiving IVIG
Currently treated patients should continue with NO changes to their current access to IVIG.
Gammagard inventory is beginning to stabilize reducing vial size substitutions.
Patients waiting for SCIG
Patients currently in the queue to start SCIG should expect no delay in their training.
We appreciate everyone’s concern and patience during this shortage.
If you have any questions or concerns about your treatment please contact your healthcare provider.
We will continue to update you, and work with Canadian Blood Services and industry, for the patient, ensuring that patient care is the primary concern to all involved.